Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheena McCormack

Showing results (1-10 of 117) with videos related to

Pageof 12
Sort By:
The Lancet. HIV|October 22, 2018
What happens when PrEP is scaled up? Results from EPIC-NSWSheena McCormack
Current Opinion in Infectious Diseases|April 20, 2002
Vaginal microbicidesSheena McCormack
The Lancet. Infectious Diseases|January 3, 2016
The role of progestins in HIV acquisition in young womenGita Ramjee, Sheena McCormack
Current Opinion in HIV and AIDS|July 26, 2019
Editorial: Concentrated epidemics: time for a rethinkSheena McCormack, Rachel Baggaley
The Lancet. HIV|May 27, 2017
Long-acting cabotegravir for prevention: hope versus realitySheena McCormack, Marta Boffito
Current Opinion in HIV and AIDS|December 4, 2015
Welcome to the preexposure prophylaxis revolutionJared Baeten, Sheena McCormack
The Lancet. HIV|October 2, 2023
Optimising oral PrEP while awaiting long-acting cabotegravirSheena McCormack, Mackenzie Leigh Cottrell
The Lancet. HIV|July 23, 2017
Vaginal dysbiosis and pre-exposure prophylaxis efficacyJanneke van de Wijgert, Sheena McCormack
AIDS (London, England)|November 3, 2010
The last decade of microbicide clinical trials in Africa: from hypothesis to factsGita Ramjee, Anatoli Kamali, Sheena McCormack
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 28, 2022
Pre-Exposure Prophylaxis for HIV Infection as a Public Health ToolChris Beyrer, Sheena McCormack, Andrew Grulich
Pageof 12

Showing results (1-10 of 117) with videos related to

Sort By:
Pageof 12
The Lancet. HIV|October 22, 2018
What happens when PrEP is scaled up? Results from EPIC-NSWSheena McCormack
Current Opinion in Infectious Diseases|April 20, 2002
Vaginal microbicidesSheena McCormack
The Lancet. Infectious Diseases|January 3, 2016
The role of progestins in HIV acquisition in young womenGita Ramjee, Sheena McCormack
Current Opinion in HIV and AIDS|July 26, 2019
Editorial: Concentrated epidemics: time for a rethinkSheena McCormack, Rachel Baggaley
The Lancet. HIV|May 27, 2017
Long-acting cabotegravir for prevention: hope versus realitySheena McCormack, Marta Boffito
Current Opinion in HIV and AIDS|December 4, 2015
Welcome to the preexposure prophylaxis revolutionJared Baeten, Sheena McCormack
The Lancet. HIV|October 2, 2023
Optimising oral PrEP while awaiting long-acting cabotegravirSheena McCormack, Mackenzie Leigh Cottrell
The Lancet. HIV|July 23, 2017
Vaginal dysbiosis and pre-exposure prophylaxis efficacyJanneke van de Wijgert, Sheena McCormack
AIDS (London, England)|November 3, 2010
The last decade of microbicide clinical trials in Africa: from hypothesis to factsGita Ramjee, Anatoli Kamali, Sheena McCormack
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 28, 2022
Pre-Exposure Prophylaxis for HIV Infection as a Public Health ToolChris Beyrer, Sheena McCormack, Andrew Grulich
Pageof 12